TORONTO, Canada I March 17, 2014 I Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (ATE.V) is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans. ATB-346 targets the global need for a GI-safe anti-inflammatory painkiller, a growing market that currently generates annual sales of over $12 billion. Said Chief Scientific Officer Dr. John Wallace, “We are delighted that the planned pre-clinical studies have been finished, and that these studies confirm and expand upon the extensive academic work already conducted on ATB-346. We are grateful to our partners and service providers for their assistance, which has enabled us to conduct these studies on schedule.” CEO Dan Legault added, “It is a significant milestone for Antibe to have completed its planned pre-clinical work on ATB-346. We look forward to sharing additional progress with Antibe’s stakeholders as we proceed with an application to Health Canada for permission to initiate the first human trials later this year.”
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. originates, develops and out-licenses patent-protected new pharmaceuticals that are improved versions of existing drugs. These improvements are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body to regulate a range of fundamental cellular processes. The Corporation’s drug design methodologies involve chemically linking an existing off-patent drug (“base drug”) to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation, pain or vascular dysfunction, the Corporation’s methodologies can efficiently produce improved versions of a number of existing drugs. Notably, Antibe’s products are themselves fully patent-protectable and may benefit from the predictable toxicity and effectiveness profiles of the base drug.
SOURCE: Antibe Therapeutics
Post Views: 201
TORONTO, Canada I March 17, 2014 I Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (ATE.V) is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans. ATB-346 targets the global need for a GI-safe anti-inflammatory painkiller, a growing market that currently generates annual sales of over $12 billion. Said Chief Scientific Officer Dr. John Wallace, “We are delighted that the planned pre-clinical studies have been finished, and that these studies confirm and expand upon the extensive academic work already conducted on ATB-346. We are grateful to our partners and service providers for their assistance, which has enabled us to conduct these studies on schedule.” CEO Dan Legault added, “It is a significant milestone for Antibe to have completed its planned pre-clinical work on ATB-346. We look forward to sharing additional progress with Antibe’s stakeholders as we proceed with an application to Health Canada for permission to initiate the first human trials later this year.”
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. originates, develops and out-licenses patent-protected new pharmaceuticals that are improved versions of existing drugs. These improvements are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body to regulate a range of fundamental cellular processes. The Corporation’s drug design methodologies involve chemically linking an existing off-patent drug (“base drug”) to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation, pain or vascular dysfunction, the Corporation’s methodologies can efficiently produce improved versions of a number of existing drugs. Notably, Antibe’s products are themselves fully patent-protectable and may benefit from the predictable toxicity and effectiveness profiles of the base drug.
SOURCE: Antibe Therapeutics
Post Views: 201
